Alterome Therapeutics
PrivateLast Round
Series B
Apr 3, 2024
Total Funding Raised
$231M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Alterome Therapeutics operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series B round in April 2024.
Alterome Therapeutics is a biopharmaceutical company that develops alteration-specific targeted therapies for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alterome Therapeutics Comparables
Compare Alterome Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Terremoto Biosciences | 90% | |
| Atavistik Bio | 89% | |
| Nested Therapeutics | 80% |
For institutional investors. Book with your work email.
Alterome Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 3, 2024 | ||||
| Series A Extension | Nov 2, 2022 | ||||
| Series A | Jan 19, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Alterome Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boxer Capital | Series A Extension, Series B, Series A |
| Digitalis Ventures | Series B |
| Vida Ventures | Series A Extension, Series B, Series A |
| Blue Owl Capital | Series B |
| OrbiMed | Series B, Series A Extension, Series A |
| Invus Opportunities | Series B |
| Canaan Partners | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors increased 41% MoM, reaching 5K.
- Feb 2, 2026
Leonardo Faoro appointed as new Chief Medical Officer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 27, 2026
Alterome Therapeutics, Inc. announces that first clinical data from the Phase 1/1b trial of ALTA3263 are presented in a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on Nov 20th '26.
- hiresSep 8, 2026
On Sep 8th '26, Alterome Therapeutics, Inc. appoints Johanna Mylet as chief financial officer in California to oversee financial strategy and operations, including capital formation, financing activities and investor relations.
- hiresSep 8, 2026
Alterome Therapeutics, Inc. appoints Johanna Mylet as chief financial officer on Sep 8th '26 in California, where she oversees financial strategy and operations as the clinical-stage biotechnology company advances its KRAS-targeting oncology pipeline.
- receives_financingSep 8, 2026
Alterome Therapeutics, Inc. raises more than $231M in venture capital to date.
For institutional investors. Book with your work email.
Alterome Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Alterome Therapeutics's valuation, stock price, and market status.
Is Alterome Therapeutics a public or private company?
Alterome Therapeutics is a private company.
What is the current stock price of Alterome Therapeutics?
Alterome Therapeutics is a private company, so its shares have no public market price. Caplight tracks Alterome Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Alterome Therapeutics worth (valuation)?
Valuation information for Alterome Therapeutics is not publicly available.
Can I buy Alterome Therapeutics stock?
Alterome Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Alterome Therapeutics's last funding round?
Alterome Therapeutics's most recent funding round was Series B on April 3, 2024.
Who are the main investors in Alterome Therapeutics?
Key investors in Alterome Therapeutics include OrbiMed, Colt Ventures, Goldman Sachs Alternatives.
Will Alterome Therapeutics IPO soon?
No public IPO plans have been announced for Alterome Therapeutics.
How can I track Alterome Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Alterome Therapeutics's shares on secondary markets.